01—Abstract
Summary
Summary of the 10-Q filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
International Flavors & Fragrances Inc. (IFF) reported net sales of $2.764 billiona for the second quarter of 2025, down from $2.889 billion a year earlier, with net income attributable to IFF shareholders of $612 million versus $170 million.
The quarterly result was helped by a $488 millionb gain on extinguishment of debt and a one-time tax benefit of $359 million tied to the entity realignment project. For the six months, the company posted a net loss attributable to IFF shareholders of $406 million, driven primarily by a $1.153 billion goodwill impairment related to the Food Ingredients reporting unit. Net sales for the six months were $5.607 billion, compared with $5.788 billion in the prior year period.
The filing reflects significant portfolio changes. The Pharma Solutions disposal group was sold on May 1, 2025, for gross cash proceeds of approximately $2.564 billionc, and the Nitrocellulose business was sold on May 9, 2025. Proceeds were largely used in May 2025 to fund tender offers for senior notes with an aggregate purchase price of $2.0 billion, and the company also repaid the remaining balance of its 2026 Term Loan Facility.
Total debt fell to $6.184 billiond at June 30, 2025 from $8.977 billion at December 31, 2024. Cash and cash equivalents rose to $816 million.
After the quarter end, on August 5, 2025, the company announced a new $500 million share repurchase authorization and an agreement to divest its soy crush, concentrates and lecithin business, with closing expected in the fourth quarter of 2025. The filing also discloses a provision of $42 million related to U.S. class action lawsuits in the fragrance business and ongoing antitrust investigations by several regulators.
02—Key points
Key Highlights
- Q2 2025 net sales were $2.764 billion, down from $2.889 billion, while net income attributable to IFF shareholders rose to $612 million from $170 million.
- Six-month 2025 results include a net loss attributable to IFF shareholders of $406 million, driven by a $1.153 billion goodwill impairment on the Food Ingredients reporting unit.
- Q2 2025 results include a $488 million gain on extinguishment of debt and a one-time tax benefit of $359 million from the entity realignment project.
- The Pharma Solutions disposal group was sold May 1, 2025 for gross cash proceeds of approximately $2.564 billion, and the Nitrocellulose business was sold May 9, 2025 for approximately $161 million in cash proceeds.
- Total debt decreased to $6.184 billion at June 30, 2025 from $8.977 billion at December 31, 2024, following tender offers of $2.0 billion for senior notes.
- A new $500 million share repurchase program and a definitive agreement to sell the soy crush, concentrates and lecithin business were announced on August 5, 2025.
- A $42 million provision was recorded for U.S. class action lawsuits related to the fragrance business, and antitrust investigations remain ongoing.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, International Flavors & Fragrances kept $0.31.
- Revenue$1.92B100.0%
- Cost of revenue−$1.09B57.1%
- Gross profit$824.0M42.9%
- Operating costs−$682.0M35.5%
- Operating income$142.0M7.4%
- Interest, other & tax$457.0M23.8%
- Net income$599.0M31.2%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 5, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $1.92B$2.89B | −33.6% |
| Cost of Revenue | $1.09B$1.82B | −39.9% |
| Gross Profit | $824.00M$1.07B | −22.8% |
| R&D Expenses | $170.00M$173.00M | −1.7% |
| SG&A Expenses | $409.00M$493.00M | −17.0% |
| Operating Income | $142.00M$191.00M | −25.7% |
| Interest Expense | $61.00M$79.00M | −22.8% |
| Net Income | $599.00M$170.00M | +252.4% |
| EPS (Basic) | $2.34$0.67 | +249.3% |
| EPS (Diluted) | $2.33$0.66 | +253.0% |
| Shares Outstanding (Basic) | 256.00M255.00M | +0.4% |
| Shares Outstanding (Diluted) | 257.00M256.00M | +0.4% |
05—Questions
Frequently Asked Questions
Why did IFF report a large net income in the second quarter but a net loss for the first six months?
The second quarter benefited from a $488 million gain on extinguishment of debt and a one-time tax benefit of $359 million tied to the entity realignment project. The six-month period, however, includes a $1.153 billion goodwill impairment related to the Food Ingredients reporting unit, which produced a net loss attributable to IFF shareholders of $406 million.
How did the divestitures affect IFF's balance sheet and debt?
The company received substantial proceeds from the Pharma Solutions and Nitrocellulose sales in May 2025 and used them largely to fund $2.0 billion in tender offers for senior notes, which carried a value of $2.5 billion, and to repay the remaining 2026 Term Loan Facility balance. Total debt declined to $6.184 billion from $8.977 billion at year-end 2024, and cash and cash equivalents increased to $816 million.
What drove the decline in sales and how did segments perform?
Consolidated net sales decreased 4% in the second quarter on a reported basis, largely due to divestiture impacts of approximately $193 million. On a comparable currency neutral basis, total sales increased 3%. Taste and Health & Biosciences grew, Food Ingredients and Scent were roughly flat on a reported basis, and Pharma Solutions declined sharply due to the divestitures.
What corporate actions were announced after the quarter ended?
On August 5, 2025, IFF announced a new share repurchase program with a total value of $500 million, with no specified term, to be funded from available cash and operating cash flow. The company also agreed to divest its soy crush, concentrates and lecithin business, with closing expected in the fourth quarter of 2025.
What legal and regulatory risks does the filing disclose?
The filing discloses a $42 million provision within selling and administrative expenses for anticipated settlements of U.S. class action lawsuits related to the fragrance businesses. It also describes ongoing investigations by the European Commission, the UK Competition and Markets Authority, the U.S. Department of Justice, and other authorities into potential anticompetitive conduct in fragrance businesses. The company states it cannot predict the outcome, and adverse results could lead to significant fines or payments.
06—Continue